Enlivex (ENLV) Net Equity Issued and Repurchased (2013 - 2025)
Enlivex (ENLV) posted quarterly Net Equity Issued and Repurchased of $197000.0 for Q1 2025, down 62.4% year-over-year from $524000.0 in Q1 2024, and down 62.4% quarter-over-quarter from $524000.0 in Q1 2024.
Enlivex (ENLV) Net Equity Issued and Repurchased (2013 - 2025) Analysis & Trends
Enlivex's Net Equity Issued and Repurchased history runs 8 years deep, the most recent figure standing at $197000.0 for Q1 2025.
- In Q1 2025, Net Equity Issued and Repurchased fell 62.4% year-over-year to $197000.0; the TTM figure through Mar 2025 stood at $763000.0 (down 13.69% YoY), while the FY2017 annual figure was $8.1 million, up 32.29% from the prior year.
- Net Equity Issued and Repurchased for Q1 2025 stood at $197000.0, down from $524000.0 in the prior quarter.
- The five-year high for Net Equity Issued and Repurchased was $524000.0 in Q1 2024, with the low at $42000.0 in Q2 2023.
- The 3-year median for Net Equity Issued and Repurchased is $257500.0 (2023), against an average of $270250.0.
- The sharpest annual moves came in 2024 and 2025: Net Equity Issued and Repurchased soared 64.78% in 2024, then plunged 62.4% in 2025.
- Enlivex's Net Equity Issued and Repurchased stood at $42000.0 in 2023, then jumped by 1147.62% to $524000.0 in 2024, then slumped by 62.4% to $197000.0 in 2025.
- Business Quant data shows ENLV's Net Equity Issued and Repurchased at $197000.0 in Q1 2025, $524000.0 in Q1 2024, and $42000.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Enlivex | 4.51 Mn | -1.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 197,000.00 |
| Mar 31, 2025 | 197,000.00 |
| Mar 31, 2024 | 524,000.00 |
| Mar 31, 2024 | 524,000.00 |
| Jun 30, 2023 | 42,000.00 |
| Jun 30, 2023 | 42,000.00 |
| Mar 31, 2023 | 318,000.00 |
| Mar 31, 2023 | 318,000.00 |
| Jun 30, 2019 | 3.00 Mn |
| Jun 30, 2019 | 3.00 Mn |
| Mar 31, 2019 | 4.71 Mn |
| Mar 31, 2019 | 4.71 Mn |
| Dec 31, 2017 | 8.05 Mn |
| Dec 31, 2017 | 8.05 Mn |
| Dec 31, 2016 | -1,000.00 |
| Dec 31, 2016 | -1,000.00 |
| Jun 30, 2016 | -106,000.00 |
| Jun 30, 2016 | -106,000.00 |
| Mar 31, 2016 | 6.20 Mn |
| Mar 31, 2016 | 6.20 Mn |